Filter Results



Quantitative immunoassay for Bevacizumab. CE Marked. For IVD Use.

SKU: KBI1016

In Stock

  • Details
  • Product Specifications
  • Citations
  • Documents
Bevacizumab is a recombinant Human IgG;κ monoclonal antibody specific for all human vascular endothelial growth factor A (VEGF-A) isoforms. Additionally, Bevacizumab binds to and neutralizes all human VEGF-A isoforms an bioactive proteolytic fragments, but not mouse or rat VEGF.

Intended Use:
The KRIBIOLISA™ Bevacizumab ELISA is used as an analytical tool for quantitative determination of Bevacizumab in serum, plasma and cell culture supernatant.

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Bevacizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Bevacizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Bevacizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Bevacizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
Suppliers Krishgen Biosystems
Storage Condition 2-8 Deg C
Usage For In-Vitro Diagnostic Use Only

Topic : Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
Current Eye Research Volume 42, 2017 - Issue 2, Pages 315-322 .
Duygu Cam
Department of Ophthalmology, State Hospital, Tunceli, Turkey.



Are You a Supplier ?

Join Krishgen as a verified supplier to connect with quality buyers, quote for real inquiries, and get more orders!

Our Premium Suppliers

Krishgen Support